Özet:

Erectile dysfunction ED is defined as persistent inability to or maintain a penis erection sufficient for satisfactory sexual performance. Benign prostatic hyperplasia BPH is often seen at advanced age like ED, and they share a common pathophysiological mechanism. Both are major health problems that negatively affect the patient’s quality of life. As the first-line treatment, phosphodiesterase type 5 inhibitors PDE5i are used for ED, and alpha-blockers for BPH. The use of PDE5i in the treatment of lower urinary tract symptoms LUTS due to BPH, has been gaining popularity in recent years. Having therapeutic effects for both erectile function and LUTS, PDE5i are good candidates as a monotherapy in BPH patients. In this review, the current status of PDE5i therapy for patients with LUTS due to BPH is discussed

Anahtar Kelimeler: